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Abstract
Background Bone repair alteration is hypothesized for
nonunion fracture pathogenesis. Since it is involved in
osteoclast regulation, the RANK/RANKL/OPG system
(receptor activator of nuclear factor kB/its ligand/osteo-
protegerin) may play a role.
Materials and methods Serum OPG, free RANKL, bone
alkaline phosphatase (BAP), osteocalcin (OC), and urinary
deoxypyridinoline (DPD) were determined in 16 male
patients (20–39 years) with long bone atrophic nonunion
fractures. Serum markers were also measured in 18 age-
matched male controls who healed from the same type of
fractures within six months, and in 14 age-matched male
controls who were healing from the same fractures one
month after injury. One-way ANOVA and Bonferroni’s
test were used for statistical analysis.
Results Only OPG was significantly higher (0.56 sd
0.11 ng/ml) in the patients compared to healed (0.26 sd
0.04 ng/ml; P \ 0.001) and healing (0.29 sd 0.09 ng/ml;
P \ 0.001) controls. The patients’ DPD levels were nor-
mal. No correlations were found between bone markers and
the characteristics of the subjects in all groups.
Conclusions A normal steady state of bone metabolism
seems to be present in patients with atrophic nonunion
fractures, despite the high serum OPG. The reason for the
inability of the patients’ OPG to inhibit osteoclastic activity
is unknown. Osteoblast activity also appears normal, so
another cellular source of OPG can be hypothesized.
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Introduction
Shaft fracture nonunion is an unpredictable complication of
orthopedic surgery that occurs in 5–10% of all fractures
[1]. Nonunions are usually classifed into two subsets
according to callus development, hypotrophic–atrophic and
hypertrophic, which are radiologically distinguishable.
Some recent studies on animal models and on human
bioptic specimens showed that there are no vascularization
differences between both atrophic and hypertrophic non-
nion fractures and normal healing fractures [2, 3]. Fur-
thermore, an ex vivo study on bioptic samples of nonunion
neighboring tissue has evidenced that endothelial growth
factor in nonunion fractures can activate vascular repair
processes [4]. Therefore, if in nonunion fracture vascular-
ization persists, as well as the ability to promote vascular
repair, it is conceivable that nonunion development may
result from abnormal biochemical activity during bone
repair.
Bone callus formation depends on osteoblastic new
bone apposition and low osteoclastic resorption activity at
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the edge of the fractured bone. During the subsequent
remodeling phase, osteoclasts are very active. A major
paradigm of osteoclast biology has emerged with the
discovery of the receptor activator nuclear factor kB
(RANK), its ligand (RANKL), and osteoprotegerin
(OPG), which are heavily involved in bone resorption,
regulating osteoclast activity. RANK is a membrane
receptor on osteoclasts and immune system cells, and
binding with RANKL is necessary to promote differenti-
ation, survival and activation of osteoclastic cells. OPG
acts as a decoy receptor for RANKL and prevents
RANK–RANKL binding. In contrast to RANKL and
RANK, which are produced in small amounts and the
expression of which is mainly restricted to the skeletal
and immune system, OPG is produced in high concen-
trations by cells of the osteoblast lineage and by many
different tissues and cell types, such as smooth muscle,
endothelial and epithelial cells [5, 6]. It is known that
OPG serum level increases with age [5], and that the
RANK/RANKL/OPG system is involved in many diseases
with bone mineral metabolism derangement, such as
rheumatoid arthritis, Paget’s disease, osteopetrosis, and
atherosclerosis [7, 8]
To our knowledge no data are available in the literature
about the OPG/RANK/RANKL system and fracture non-
union of long bones. The aim of this study was to
investigate the relation between the OPG/RANK/RANKL
system and this type of fracture in a case–control model.
Materials and methods
Sixteen male patients with an atrophic nonunion shaft
fracture, 20–39 years old, were included in the study
(‘‘nonunion’’). No patient developed a local or systemic
infection. The first control group (‘‘healed’’) consisted of
18 age-matched male subjects who healed from the same
type of fracture and from whom blood samples were taken
within six months after the healing of the fracture.
The second control group (‘‘healing’’) consisted of 14
age-matched male subjects who healed from a shaft
fracture, and from whom blood samples had been col-
lected and stored during fracture healing within one
month from the injury. The study conforms to the
Declaration of Helsinki, was approved by the local ethics
committee, and written informed consent was obtained
from patients and controls.
Fractured patients undergoing treatment with drugs
that interfere with bone metabolism, with local or sys-
temic severe diseases, with previous same limb segment
fractures, or with previous nonunion fractures were
excluded.
A 12 h fasting blood sample was taken from each
patient and control; a 12 h fasting urinary sample was also
collected from each patient.
Osteocalcin (OC), bone alkaline phosphatase (BAP),
OPG, free RANKL and urinary deoxypyridinoline (DPD)
were measured in the patients. The same tests were
performed in controls with the exception of urinary DPD.
Free RANKL expresses as a soluble unbound fraction,
which is free to interact with its receptors (RANK, OPG).
OPG was measured using the Human Osteoprotegerin
ELISA kit (BioVendor Laboratory Medicine, Inc. Brno,
Czech Republic, Labogen-srl). The intra-assay (within-run)
coefficient of variation was 5% and the interassay (run-to-
run) coefficient of variation was 4.7%. The limit of
detection was better than 0.024 ng/ml of sample; speci-
ficity was less than 0.06%. For RANKL measurement, the
Human Serum RANKL Free ELISA kit was used (Bio-
medica Medizinprodukte GmbH & Co. KG, Wien, Austria,
Pantec), with an intra-assay coefficient of variation of 4%
and an interassay coefficient of variation of 7.5%; the limit
of detection was better than 0.08 pmol/l. To measure BAP,
OC and DPD, the Metra ELISA kit (Quidel; San Diego,
CA, USA) was used; here, the intra-assay and interassay
coefficients of variation (CV) for each marker were,
respectively, 4.96 and 5.93%, 7.83 and 6.96%, 6.06 and
4.16%.
Statistical analysis
Comparisons of the values for the three groups (nonunion
patients, healed and healing controls) were performed by
one-way ANOVA and Bonferroni multiple comparison
tests, with the level of significance (P) being \0.05. Data
are expressed as mean values and SDs.
Results
Table 1 shows the characteristics of both the patients and
the controls, the distribution of the fracture site in each
group, and the values of the serum bone markers. The only
statistically significant difference was found for the OPG
values of nonunion patients compared with both control
groups (P \ 0.001). The distributions and standard devia-
tions of the OGP values in the three groups are shown in
Fig. 1.
The mean urinary DPD measured in the patients, nor-
malized with respect to urinary creatinine, was 7.04 (SD
1.45) nmol DPD/mmol U-Cre, which is within the normal
laboratory reference range (2.07–11.80 nmol DPD/mmol
U-Cre).
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No significant correlations were found between OC,
BAP, DPD, OPG, free RANKL and the characteristics of
the nonunion patients and the controls.
Discussion
In our patients with atrophic nonunion shaft fractures, the
mean serum OPG level was significantly increased with
respect to healed and healing controls, whereas the values
of the other serum bone markers did not differ between the
three cohorts.
The significantly higher serum OPG level in the patients
may suggest an imbalance in the RANK/RANKL/OPG
system, with osteoclast downregulation promoting a net
apposition of new bone tissue. However, the patients’
radiographic images did not show callus bridges or calci-
fication between or around the fracture stumps. Moreover,
the osteoclast resorption activity marker, namely urinary
DPD, was within the laboratory reference range for the
normal population, not lower, suggesting that there was no
inhibition of osteoclastic activity in atrophic nonunion
fractures. This assessment was also confirmed by the fact
that, in spite of the higher serum OPG, free RANKL levels
in patient serum were comparable to those of all of the
controls, whereas free RANKL would be expected to be
lower for increased binding associated with the high serum
OPG.
The osteoblast activity of the patients also appeared to
be normal. Indeed, the markers of osteoblast viability and
mineralization, BAP and OC respectively, were compara-
ble in the three groups and within the normal range of
laboratory values. In this bone metabolic situation, it would
be questionable to ascribe the source of the high OPG to
osteoblasts. It appears reasonable to suppose that there
could be another unknown source of OPG, such as endo-
thelial cells from the vessels surrounding the fracture.
Some studies have investigated some biochemical
markers of bone metabolism in animals and patients, and
have found that nonunion and normal fracture healing
exhibit different behaviors [9, 10]. A study showed a
relation between human fracture healing at the 16th week
and a decline in serum osteocalcin (OC) and alkaline
phosphatase (AP) [11]. Recently, another author found that
measurements of OC, bone alkaline phosphatase (BAP)
and deoxypyridinoline (DPD) could be useful for early
diagnosis of nonunion fractures in rabbits [10].
A study showed that transforming growth factor b
(TGFb), platelet-derived growth factor, basic fibroblast
growth factor, and bone morphogenetic protein 2/4 (BMP)
were not significantly different in rabbits with nonunion
with respect to rabbits with normal healed fractures [2]. A
study found that the TGFb supergene family and BMP can
induce bone formation [12]. So far, it has not been
demonstrated that a metabolic derangement could be the
cause of the failed formation of bone callus in man.
Interpreting our data, a persistent steady state situation of
apparently normal bone metabolism leading to missed
fracture healing seems to be a possible explanation for
nonunion fractures.
Also, the high OPG serum levels in nonunion patients do
not seem to be bound to the reparatory process, considering
that OPG is not elevated in the healing controls; therefore,
it may be an indicator of metabolic derangement of bone
repair.
In our study, no correlations between any bone marker
and the characteristics of the patients and controls were
found. In the literature, a positive correlation between
serum OPG levels and the ages of normal subjects was
Table 1 Characteristics of patients and controls, and results of bone
markers measurements; values are shown as mean (SD)
Characteristic Nonunion Healing
controls
Healed
controls
16 14 18
Site of fractures
Tibia 7 8 9
Radius 1 0 2
Radius ? ulna 3 2 4
Humerus 2 2 1
Femur 3 2 2
Age (years) 28.1 (5.9) 31.4 (7.1) 32.2 (5.7)
Time after injury (months) 6–11 0.5 (0.5) 8.5 (3.4)
OPG (ng/ml) 0.56 (0.11) 0.29 (0.09)* 0.26 (0.04)*
Free RANKL (pmol/l) 0.08 (0.09) 0.16 (0.07) 0.10 (0.07)
BAP (UI/l) 24.46 (5.99) 31.56 (17.67) 24.21 (7.13)
OC (ng/ml) 7.27 (3.95) 8.60 (4.47) 8.45 (2.94)
* P \ 0.001 versus nonunion
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Fig. 1 OPG serum levels in nonunion patients and in healing and
healed controls
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described [13], but it was not confirmed in our cohorts,
probably due to the short population age range in this
study.
The relatively small population in this study and the lack
of measurements of bone reabsorption markers for the
control groups may have limited the interpretation of
possible bone metabolism differences between patients and
controls.
Nevertheless, our observations may have a practical
consequence. Even today, clinical and imaging evaluation
is the cornerstone of the diagnosis of nonunion fractures,
which is established only after six months post-injury; an
earlier diagnosis is still not achievable. OPG measurement
may provide a tool that facilitates the early identification of
nonunion fractures, so a longitudinal study could be useful
for checking this assumption.
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